Literature DB >> 15946465

Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass.

Fabio V Teixeira1, Tânia M S Novaretti, Benedito Pilon, Priscila G Pereira, Maria Fernanda C L Breda.   

Abstract

Two morbidly obese patients are reported who underwent gastric bypass and suffered nausea and vomiting 1 month after the operation. Endoscopy and upper GI series showed no evidence of stomal stenosis or other mechanical cause for a GI obstruction. Control of vomiting by current antiemetic drugs such as bromopride and ondansetrone was unsuccessful. The patients were then given Remeron Soltab (mirtazapine, Organon, Brazil) 30 mg once per day orally for 2 to 8 months. Nausea and vomiting disappeared within days after beginning the medication. Stomal stenosis is the main cause of vomiting after gastric bypass. After ruling out mechanical causes, other reasons for postoperative vomiting must be considered. Mirtazapine is a noradrenergic and specific serotonergic antidepressant, which blocks the 5HT3 receptor, leading to an antiemetic effect. It has successfully been used as an antiemetic drug in patients undergoing chemotherapy. We concluded that mirtazapine may be a successful option to treat non-mechanical postoperative vomiting in morbidly obese patients after gastric bypass.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946465     DOI: 10.1381/0960892053923923

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  9 in total

1.  Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.

Authors:  Jun Cao; Quchang Ouyang; Shusen Wang; Joseph Ragaz; Xiaojia Wang; Yuee Teng; Biyun Wang; Zhonghua Wang; Jian Zhang; Leiping Wang; Jiong Wu; Zhimin Shao; Xichun Hu
Journal:  Invest New Drugs       Date:  2020-02-08       Impact factor: 3.850

Review 2.  Newest Drugs for Chronic Unexplained Nausea and Vomiting.

Authors:  William L Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

3.  A Randomized Controlled Trial for Prevention of Postoperative Nausea and Vomiting after Laparoscopic Sleeve Gastrectomy: Aprepitant/Dexamethasone vs. Mirtazapine/Dexamethasone.

Authors:  Tarek M Ashoor; Dina Y Kassim; Ibrahim M Esmat
Journal:  Anesthesiol Res Pract       Date:  2022-04-30

Review 4.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

5.  Rapid improvement in post-infectious gastroparesis symptoms with mirtazapine.

Authors:  Shinjini Kundu; Shari Rogal; Abdulkader Alam; David J Levinthal
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 6.  Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

7.  Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series.

Authors:  Murat Coskun; Behiye Alyanak
Journal:  J Neurogastroenterol Motil       Date:  2011-07-14       Impact factor: 4.924

8.  Chronic elevation of systemic glucagon-like peptide-1 following surgical weight loss: association with nausea and vomiting and effects on adipokines.

Authors:  Noora Al-Rasheid; Rosaire Gray; Pratik Sufi; Nephtali Marina-Gonzalez; Mohammed Al-Sayrafi; Elizabeth Atherton; Vidya Mohamed-Ali
Journal:  Obes Surg       Date:  2015-02       Impact factor: 4.129

9.  Mirtazapine for symptom control in refractory gastroparesis.

Authors:  Mark Malamood; Aaron Roberts; Rahul Kataria; Henry P Parkman; Ron Schey
Journal:  Drug Des Devel Ther       Date:  2017-03-30       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.